Omeros Corp. (OMER)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$18.95-0.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OMER
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue commercial launch and expand market access of YARTEMLEA, including reimbursement and new indications development.
Stated as a priority in 2 of last 2 quarters. YARTEMLEA gross revenues grew from $11.1 million in 2026-Q1 to $32.2 million in 2026-Q2, a 190% increase. Management emphasized strong momentum and growing market acceptance, indicating the trajectory is delivering on commercial launch and market expansion.
“Strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch”
“Launched YARTEMLEA in the U.S. market with gross product sales of $11.1 million”
Continue repurchasing 2029 convertible senior notes to reduce principal, interest payments, and potential dilution.
Stated as a priority in 2 of last 2 quarters. The company repurchased $30.5 million principal of 2029 Notes in July 2026, reducing outstanding principal from $70.8 million in 2026-Q1 to $40.3 million in 2026-Q2 and eliminating $8.6 million in future interest payments. Management is delivering on this capital allocation priority.
“Completed repurchase of $30.5 million aggregate principal amount of 2029 Notes in July 2026”
“Remaining $70.8 million aggregate principal amount outstanding of 2029 Notes after repaying 2026 Notes”
Progress clinical and preclinical development of pipeline programs OMS527 for cocaine use disorder and OncotoX-AML for acute myeloid leukemia.
Stated as a priority in 2 of last 2 quarters. Management targets OMS527 inpatient clinical trial enrollment by year-end 2026 and OncotoX-AML Phase 1b trial initiation in late 2027 with ongoing IND-enabling studies. Progress is consistent with stated development timelines, indicating delivery on pipeline advancement.
“Expect to start enrollment in OMS527 inpatient clinical trial by year-end 2026; OncotoX-AML Phase 1b trial targeted for late 2027”
“OMS527 preclinical studies completed; working with FDA to initiate inpatient clinical trial by year-end 2026; OncotoX-AML IND-enabling studies underway”
Target positive cash flow and profitability supported by commercial revenues and operational improvements.
Stated as a priority in 2 of last 2 quarters. Net income was $56.1 million in 2026-Q1 and $13.2 million in 2026-Q2; net cash from operations was $4.1 million in 2026-Q2. Management targets positive cash flow in 2027, with recent revenues strengthening capital structure. The trajectory shows progress but net income declined quarter-over-quarter, indicating mixed delivery.
“Substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure”
“These successes are expected to fuel development and target positive cash flow in 2027”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Over the trailing year it converted 5.37x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.